Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etravirine in treatment-experienced HIV-1 infected infants and children under 6 years
2012-002630-36Phase 2
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etravirine in Human immunodeficiency virus infection type 1, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Steady-state pharmacokinetics of etravirine and Antiretroviral activity through 48 weeks.
02
Drugs
etravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-002630-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002630-36.